Surgical resection of recurrent differentiated thyroid cancer: patterns, detection, staging, and treatment of 683 patients
Nan Liang,Han Zhang,Chengqiu Sui,Rui Du,Canxiao Li,Jingting Li,Gianlorenzo Dionigi,Daqi Zhang,Hui Sun
DOI: https://doi.org/10.3389/fendo.2023.1301620
IF: 6.055
2023-12-06
Frontiers in Endocrinology
Abstract:Background Despite improvements in overall survival, the recurrence of differentiated thyroid cancer (DTC) is becoming more common and remains a challenge necessitating accurate reappraisal of the patient. This study aimed to describe the characteristics, reasons, morbidity, and strategies of second operations for DTC. Methods This was a retrospective observational study of patients with DTC who underwent a second surgery between June 2008 and June 2021 in the Department of Thyroid Surgery at China–Japanese Union Hospital, Jilin University, P.R. China. All clinical characteristics were recorded, and the analysis was estimated using SPSS. Results Second surgeries were detected in 683 patients. The proportion of second operations changed with the update of international guidelines from 2015 ( P < 0.001). The true recurrence rate progressively increased from 21.3% to 61.5%. The rate of an “absence of preoperative FNA” or an “absence of intraoperative pathology at first surgery” decreased from 49.8% to 12.7%, while that of a “misdiagnosis of preoperative FNA at second surgery” decreased from 10% to 1.8%. The most common tumor location during the second surgery was the lateral lymph nodes (n = 104, 36.5%), with a median time to relapse of 36 months. Completion of thyroidectomy and lymph node dissection correlated with the second operation. Conclusion After 2015, second surgeries were more standardized, the incidence of complications decreased, and real recurrence became the most common reason for a second DTC surgery.
endocrinology & metabolism